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Background: This study investigated the clinical importance of linked angiogenetic biomarkers to chemotherapy, combined
with the anti-vascular endothelial growth factor A (anti-VEGF-A), as a first-line treatment in patients with metastatic colorectal
cancer (mCRC).
Methods: A total of 230 patients from a randomised phase III study were included. The primary microRNA-126 (pri-miRNA-126)
A24G single-nucleotide polymorphism and the mature miRNA-126 were analysed by PCR using genomic DNA (full blood) and
formalin-fixed paraffin-embedded tissue sections, respectively. The epidermal growth factor-like domain 7 (EGFL7) protein was
visualised and quantified using immunohistochemistry.
Results: High tumour expression of miRNA-126 was significantly related to a longer progression-free survival. The independent
prognostic value of miRNA-126 was confirmed using a Cox regression analysis (hazard ratio¼ 0.49, 95% confidence interval¼ 0.29–0.84,
P¼ 0.009). Although not significant, a relationship between EGFL7 expression and response rates is suggested, with
EGFL7 expression at the invasive front being lower in responding patients than in the non-responders (P¼ 0.063).
Conclusion: The results validate the previous findings on the prognostic value of miRNA-126 in mCRC and may suggest a
relationship between treatment efficacy and EGFL7 expression. As miRNA-126 may target VEGF-A as well as EGFL7, the results
may provide predictive information in relation to next-generation anti-angiogenetics.
Each year, 1.2 million people worldwide are diagnosed with
colorectal cancer (CRC), making it the third most common cancer,
with an estimated annual mortality of 0.6 million (Ferlay et al,
2010). Adding anti-angiogenetics to chemotherapy improves the
overall survival (OS) of patients with metastatic CRC (mCRC)
(Cao et al, 2009; Wagner et al, 2009); however, the overall benefit
in unselected patient cohorts is rather limited. Focusing on a
decade of clinical experience with anti-angiogenetic drugs,
primarily targeting the vascular endothelial growth factor A
(VEGF-A), we are still left without validated biomarkers to select
an anti-angiogenetic therapy for the fraction of patients responding
favourably to this treatment strategy.
MicroRNAs (miRNAs) represent a group of candidates in this
setting with biomarker as well as therapeutic potential. These
small, non-coding RNA fragments bind to the 30untranslated
region (30UTR) of their target transcripts, leading to an inhibition
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of the translational process (Esquela-Kerscher and Slack, 2006;
Filipowicz et al, 2008). MicroRNA-126 is expressed in endothelial
cells (ECs) with a high specificity and is considered essential to the
regulation of blood vessel integrity (Fish et al, 2008; Wang et al,
2008). The VEGF-A mRNA is an miRNA-126 target, and studies
have argued for a role of miRNA-126 in regulating VEGF-A-
mediated signal transduction (Parker et al, 2004; Fish et al, 2008;
Kuhnert et al, 2008; Wang et al, 2008). MicroRNA-126 is
downregulated in several malignant tumours, (Guo et al, 2008;
Li et al, 2010; Meister and Schmidt, 2010) and is often referred to
as a tumour suppressor (Schepeler et al, 2012).
A single miRNA can regulate hundreds of target mRNAs, and
consequently, a polymorphism affecting the biogenesis of a given
miRNA may regulate the expression of multiple genes in a given
molecular pathway. A study of mCRC argued for a possible
predictive value of primary-miRNA (pri-miRNA) single-nucleotide
polymorphisms (SNPs) with regard to first-line chemotherapy
(Boni et al, 2011). Recently, one SNP in the pri-miRNA-126, A24G
(rs4636297), was identified with a possible influence on the
bioavailability of the mature miRNA-126 transcript
(Harnprasopwat et al, 2010). The clinical importance of this SNP
is largely unknown.
MicroRNA-126 is located within the intron 7 of the epidermal
growth factor (EGF)-like domain 7 (EGFL7) gene, and EGFL7
mRNA has been identified as a potential target of miRNA-126
(Sun et al, 2010); (Figure 1A). The EGFL7 protein is important for
vascular system development and is expressed postnatally in highly
vascularised tissues. It is upregulated at sites of pathological
angiogenesis and acts as a chemo-attractant in the recruitment of
ECs (Campagnolo et al, 2005). EGFL7 is an EC-derived protein
that is secreted into the extracellular matrix (ECM), where it
remains in close vicinity to the ECs, regulating their spatial
organisation in the vascular sprouts and guiding the migration of
the sprouts through the ECM (Schmidt et al, 2007). The presence
of EGFL7 is necessary for the tubulogenesis of blood vessels
(Parker et al, 2004).
A prognostic role of miRNA-126 in patients with CRC has been
proposed (Schepeler et al, 2008; Hansen et al, 2012), and we have
previously shown that miRNA-126, estimated using in situ
hybridisation (ISH) in patients with mCRC, may be predictive of
chemotherapy efficacy (Hansen et al, 2012). The possible
predictive value in a setting of anti-VEGF-A therapy remains to
be analysed. The clinical importance of EGFL7 is still sparse. An
anti-EGFL7 monoclonal antibody has been developed (Genen-
tech), and preclinical tests have suggested a synergistic effect of
combining anti-VEGF-A and anti-EGFL7. This is currently being
tested in the CONGO trial (ClinicalTrials.gov identifier
NCT01399684). If positive, understanding the complex interaction
between VEGF-A, EGFL7 and miRNA-126 will become even more
important from the clinical point of view.
The aim of this translational study was to analyse the predictive
value of a set of linked angiogenetic markers at the DNA (the pri-
miRNA-126 SNP), RNA (mature miRNA-126) and protein
(EGFL7) levels in relation to first-line chemotherapy combined
with bevacizumab in patients with mCRC.
MATERIALS AND METHODS
Patient characteristics. The phase III Nordic ACT (I) multicentre
study included 249 patients from Sweden and Denmark between
October 2007 and October 2009 (ClinicalTrials.gov identifier
NCT00598156). All the patients were previously untreated, had
histologically verified mCRC and had received first-line
chemotherapyþ bevacizumab (anti-VEGF-A). The patients were
initially treated with induction chemotherapy, consisting of
fluorouracil and leucovorin or capecitabine in combination with
either oxaliplatin (FOLFOX or XELOX, n¼ 183) or irinotecan
(FOLFIRI or XELIRI, n¼ 66) plus bevacizumab. Six cycles were
given in the case of XELOX/XELIRI and nine cycles when
FLOFOX/FOLFIRI was used. One hundred and sixty-two patients
were subsequently randomised to maintenance therapy consisting
of bevacizumab±erlotinib (an anti-epidermal growth factor
receptor (EGFR)) until progression or unacceptable toxicity. The
primary reasons for exclusion after induction therapy were
progressive disease, planned surgery with curative intent and
adverse events. Adjuvant treatments that completed 46 months
prior to study entry were allowed.
Information on patient characteristics and treatment efficacy
was recorded according to good clinical practice. The study was
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Figure 1. (A) Illustration of an endothelial cell, demonstrating the interaction of the investigated parameters. (B) Diagram illustrating the
investigated parameters: pri-miRNA-126 SNP; mature miRNA-126; EGFL7 protein, and sample availability. EGFL7 analyses of samples
(tumour resections) from four patients were not possible as all the available tissue was used in the initial qPCR profiling of miRNA-126. Thus,
immunohistochemical staining was performed on 122 resections and 47 biopsies, respectively. EGFL7 tumour was consequently scored in 169
samples, whereas EGFL7 invasive front was scored in 122 samples. Abbreviations: Pri-miRNA-126, primary microRNA-126; miRNA-126, microRNA-
126; EGFL7, epidermal growth factor-like domain 7; SNP, single nucleotide polymorphism; pre-miRNA-126, precursor microRNA-126; Dicer, The
RNAse III enzyme responsible for excising the miRNA duplex from the pre-miRNA hairpin.
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approved by the Regional Scientific Ethical Committee and the
Danish Data Protection Agency (ID VF-20060115, 2007-41-0252),
and informed consent was obtained from all the patients enroled in
the study.
Sampling. Samples were available from 230 of the 249 included
patients (92%). Blood samples, available from 222 patients, were
collected in 5–10-ml EDTA tubes and sent to Vejle Hospital to be
frozen at  80 oC and stored until DNA analysis. All the
histological samples followed routine formaldehyde fixation and
paraffin embedding (FFPE). The available tissue samples (n¼ 173)
originated from a resected tumour in 126 (73%) patients and from
a diagnostic biopsy in 47 (27%) patients. Analysis of samples
(tumour resections) from four patients was not possible as all the
available tissue had been used in the initial qPCR profiling of
miRNA-126. Thus, immunohistochemical staining was performed
in 122 resections and 47 biopsies, respectively. Tissue sections for
miRNA and immunohistochemical analyses were cut adjacently
from the same FFPE tissue block.
Samples available for analysis are illustrated in Figure 1B. The
analyses presented in this study vary according to the contributions
from the different sample sources. Thus, individual sample sizes
will be presented for each analysis.
Evaluation of treatment efficacy. Response rates (RR), available
from all patients, were assessed according to the Response
Evaluation Criteria In Solid Tumours (RECIST 1.0) (Therasse
et al, 2000). Evaluations were performed on the basis of clinical and
radiologic examination, using CT scans of the chest and abdomen.
Responding patients were classified as having either complete
response (CR) or partial response (PR), whereas non-responding
patients were classified as having either stable disease (SD) or
progressive disease (PD). Response rates were used to evaluate the
efficacy of the induction therapy, whereas progression-free survival
(PFS) was the endpoint of the maintenance treatment. Progres-
sion-free survival was calculated from the time of randomisation
(after completion of the induction therapy) until the date of the last
CT scan without PD.
Pri-miRNA-126 SNP analysis. The SNP analysed in this study,
pri-miRNA-126 A24G SNP (rs 4636297), is located in the EGFL7
gene in intron 7 and is the only known SNP in this region. It was
chosen based on a previous publication indicating the functional
importance of this SNP (Harnprasopwat et al, 2010), and because
of an allele distribution allowing a meaningful comparison with the
mature miRNA-126 transcript as well as the EGFL7 protein
expression.
Germline DNA was isolated from the whole blood of 222
patients using the Maxwell method, according to the user manual
(Promega Corporation, Madison, WI, USA) (http://www.prome-
ga.com/tbs/tm284/tm284.pdf). Genotyping was performed by PCR
analysis using the ABI PRISM 7900 HT fast real-time PCR system
(Applied Biosystem, Foster City, CA, USA). The primer sequences
were as follows: forward 50-CACTTCAAACTCGTACCGTG
AGTAA, reverse 50-CAGGGCTATGCCGCCTAA, and probes:
6FAM-GCGCTTTCGATGCG and VIC-CGGCGTTTTCGATG.
The analysis was performed as previously described (Hansen
et al, 2011). All the samples met the quality value threshold of 98%.
All the blood samples were successfully processed and analysed,
blinded of patient outcome, at the same institution (Vejle Hospital,
Denmark).
MicroRNA-126 analysis. The qPCR profiling of miRNA-126 in
4-mm tissue sections from small diagnostic biopsies may introduce
bias due to heterogeneity. Hence, it was decided to perform
miRNA-126 quantification on only whole-tumour resection speci-
mens. This was consequently performed on 126 samples and
carried out using Exiqon A/S (Vedbaek, Denmark).
Initially, the RNA was extracted in accordance with an
optimised Qiagen FFPE purification protocol. Afterwards, 10 ng
of RNA was reverse-transcribed (RT) in 10-ml reactions using the
miRCURY LNA Universal RT miRNA PCR, Polyadenylation and
cDNA synthesis kit (Exiqon). cDNA was diluted by 100 and
assayed in 10-ml PCR reactions according to the miRCURY LNA
protocol. MicroRNA-126, miRNA-16, miRNA-103 and negative
controls were assayed using qPCR on the microRNA Ready-to-Use
PCR, Pick-n-Mix panel. Amplification was performed using a
LightCycler 480 Real-Time PCR System (Roche) in 384-well plates.
Amplification curves were analysed using the Roche LC software,
both for the determination of the crossing point (Cp) and for a
melting curve analysis.
A built-in quality control would remove the reactions with
several melting points, melting points not within the assay
specification, an amplification efficacy of o1.6, or the reactions
within 5 Cp values of the negative control reactions. Furthermore,
RNA spike-in control (Sp6) was added to the RT reaction in order
to evaluate both the RT reaction and the following qPCR reaction.
All samples passed the quality control, and the results showed
similar Cp values across all the samples, indicating successful
RT-qPCR analyses. The qualities of the samples were comparable
(samples were very similar in miRNA content); they were
processed reproducibly in triplicates, and the mean value was
used in later analyses.
The normalisation of the miRNA expression data represents an
important step in data analysis, potentially influencing the final
results. So far, there does not seem to be an optimal solution to this
challenge. According to Chang et al (2010), several combinations
of reference genes (miRNAs) have been recommended for the
normalisation of RT-qPCR data in CRC. MicroRNA-16 was the
single most suitable reference gene.
The normalisation procedure in the present analysis was
optimised to correct for potential differences in samples. In this
data set, the average values of miRNA-16 and miRNA-103 were
chosen based on previous experience with Exiqon A/S. Thus, the
miRNA-126 expression values are relative values without
dimension.
EGFL7 and caldesmon immunostaining. Tissue sections were
stained using antibodies against EGFL7 and caldesmon, aiming at a
differentiation between the mature and immature microvessels.
Four-micrometre-thick tissue sections were mounted on coated
slides and dried for half an hour at 60 oC and then overnight at
37 oC. Deparaffinisation was performed in estisol for 10min at
room temperature, followed by rehydration in graded alcohol
solutions (99–70%). Endogenous peroxidase was blocked by
adding hydrogen peroxide (3%) for 5min. Antigene unmasking
were achieved by microwave oven heat-induced epitope retrieval,
using a TEG buffer (TRIS 10mM, EGTA 0.5mM, Titriplex-VI,
Darmstadt, Germany) at pH 9 for 10min at 1000W and for 15min
at 440W. Tris-buffered saline (TBS)/Tween pH 7.6 was added for
5min after cooling at room temperature. The anti-EGFL7 was a
rabbit polyclonal antibody (ab115786, Abcam, Cambridge, UK)
used in a 1 : 200 dilution and incubated for 90min. The anti-
caldesmon was a mouse monoclonal antibody (Clone h-CD,
M3557, Dako, Glostrup, Denmark) used in a 1 : 50 dilution and
incubated for 30min. After washing in TBS/Tween, the visualisa-
tion was performed using Dako’s EnVision G|2 Doublestain System
(Rabbit/Mouse, DABþ /Permanent Red, code K5361, Dako) for
30min. The EGFL7 was visualised using Polymer/HRP (brown)
and caldesmon was visualised using Polymer/AP (red). Nuclei
staining was obtained using Mayer haematoxylin solution.
The specificity of the anti-EGFL7 antibody was tested using pre-
treatment with the TEG buffer at pH 9. EGFL7 Recombinant
Protein, Novus H00051162-P01 4ml and Dako Flex buffer K8007
200 ml were used along with 1 ml of the anti-EGFL7 antibody in a
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1 : 200 dilution. The solution was incubated for 30min, followed by
90min of incubation. This resulted in only a few ECs demonstrat-
ing focal, faint staining, and no background staining or staining of
tumour cells was observed.
Scoring of EGFL7 expression
EGFL7 expression. Any dark brown EGFL7-positive, caldesmon-
negative, stained structure with an endothelial morphology was
considered to be countable. Tissue sections were initially scanned
at low power ( 40), and five random areas in the tumour and five
at the deepest invasive front were selected for quantification at
 100 power. The average scores from the five areas in the tumour
and the invasive front were used for later analyses. Assessment was
achieved using a point-counting graticule with 25 points (model
WHN10X-H-1-3, Olympus, Ballerup, Denmark). Each point
overlaying a countable structure resulted in a count, and the final
estimate consequently refers to a volume fraction.
Interobserver variability. Before the scoring of all the sections by
one investigator (TFH, unaware of the patient outcome), an
interobserver variability test was performed between the two
investigators (TFH and FBS). Interobserver variability was assessed
for EGFL7 expression in the tumour and at the invasive front in a
sub-sample of 17 tissue sections. Linear correlation analysis
demonstrated an acceptable correlation between the EGFL7
estimates obtained at the invasive front (r¼ 0.56, P¼ 0.02). The
EGFL7 estimates from the tumour area demonstrated a rather
similar, although not significant (r¼ 0.43, P¼ 0.08), correlation.
The results were considered to be acceptable based on the
subjective nature of immunohistochemical scoring in general and
the rather small sample set used in the test.
Biopsies/resections. The presented EGFL7 tumour scoring was
applied to all the tissue samples (n¼ 169), resections and
diagnostic biopsies, whereas invasive front scoring was exclusively
carried out in the tumour resections (n¼ 122).
Table 1. Patient characteristics
Pri-miRNA-126 EGFL7
Number (%) A24G SNP (genotypes, n¼222) miRNA-126 (medians) Tumour
(medians)
Invasive front
(medians)
(N¼230) AA AG GG N¼126 N¼169 N¼122
Gender
Male 133 11 58 60 2.32 0.4 0.4
Female 97 16 42 35 2.30 0.6 0.6
Age (years)a
Mean (s.d.) 62.0 (9.3) — — — — — —
Range 26–81 — — — — — —
4Mean 130 17 59 50 2.42 0.5 0.5
pMean 100 10 41 45 2.20 0.5 0.4
ECOG PS
0 159 (69) 22 64 68 2.31 0.5 0.4
1–2 71 (31) 5 36 27 2.33 0.5 0.8
Resection
Yes 150 (65) 19 62 61 2.32 0.4 0.4
No 80 (35) 8 38 34 0.5
Localisation
Colon 137 (60) 15 61 55 2.32 0.5 0.6
Rectum 77 (33) 9 32 34 2.26 0.4 0.4
Colonþ rectum
(synchronous)
16 (7) 3 7 6 2.38 0.4 0.4
Metastatic Sites
1 120 (52) 15 44 57 2.33 0.5 0.5
X2 110 (48) 12 56 38 2.28 0.5 0.4
Adjuvantb
Yes 32 (15) 4 14 14 2.19 0.4 0.4
No 187 (85) 23 84 80 2.44 0.5 0.5
Abbreviations: ECOG PS¼Eastern Cooperative Oncology Group performance status; EGFL7¼ epidermal growth factor-like domain 7; miRNA-126¼microRNA-126; Pri-miRNA-126¼primary
microRNA-126; SD¼ standard deviation; SNP¼ single-nucleotide polymorphism. The pri-miRNA-126 SNP was in Hardy–Weinberg equilibrium (P¼ 1.0).
aAge at the time of diagnosis.
bData registration incomplete.
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Statistics. The Wilcoxon rank sum test was used for a comparison
of the median values. Fisher’s exact test was used for a comparison
between the categorical parameters, whereas w2 statistics were used
to test for the Hardy–Weinberg equilibrium. A linear regression
analysis was used to investigate the linear association between the
continuous variables and to analyse the continuous outcomes
across categorical variables with more than two values, for
example, miRNA-126 expression levels across genotypes AA, AG
and GG. Survival functions were estimated using log rank tests and
illustrated using the Kaplan–Meier method. A simple Cox
regression analysis was used to estimate the hazard ratio of
individual potential prognostic variables, and variables with
P-valueso0.1 were included in a multiple Cox regression analysis.
Adjustment for multiple comparisons was not made, as the study is
hypothesis-generating in several of its aspects. All patients were
successfully followed-up until progression. A two-sided 0.05
significance level was used in all the statistical tests. All statistical
calculations were carried out using STATA 11.2 (Stata Corp.,
College Station, TX, USA).
RESULTS
Patient and sample characteristics. Patient characteristics are
shown in Table 1. The visualisation of EGFL7 and caldesmon was
successful in all the tissue sections, although the staining intensity
varied between sections (Figure 2A). Unspecific background
staining was detected in majority of the tissue sections, and more
than half of the tissue sections showed signs of tumour cell EGFL7
expression (Figures 2B and C).
Correlations. The correlations between the investigated para-
meters are shown in Table 2. The results implied a marginally
significant functional importance of the pri-miRNA-126 A24G
SNP. The G-allele-containing genotypes seemed to be associated
with a tendency towards lower miRNA-126 and EGFL7 invasive
front expression. MicroRNA-126 expression was not correlated
with EGFL7 expression, but the EGFL7-derived parameters were
significantly correlated with each other.
Response rates. The relationship between the investigated para-
meters and RR is shown in Table 3. The relationship between low
EGFL7 expression at the invasive front and response to the
induction chemotherapy, combined with anti-VEGF-A, showed a
marginal statistical significance (P¼ 0.063, Figure 3). Using the
median EGFL7 score at the invasive front (0.5) as the cutoff, the
positive predictive value of a score of p0.5 was 62% (40/65),
whereas the negative predictive value of a score of X0.6 was 65%
(37/57). None of the other investigated parameters were associated
with RR.
Survival. The miRNA-126 expression was the only investigated
parameter significantly related to PFS (P¼ 0.005, Figure 4).
Patients with high miRNA-126 expression levels had a longer
PFS on maintenance therapy. The same relationship was seen
when patients were stratified according to maintenance treatment
(data not shown).
Variables demonstrating P-values o0.1 in the simple Cox
model (Table 4) were included in the Cox regression model. An
independent prognostic value was demonstrated in the multiple
regression analysis only by miRNA-126 expression (HR¼ 0.49,
95% CI¼ 0.29–0.84, P¼ 0.009).
DISCUSSION
The present results may indicate a functional importance of the
pri-miRNA-126 SNP and validate previous results regarding the
prognostic value of miRNA-126 in patients with mCRC. The
clinical significance of EGFL7 in CRC tissue is more speculative,
suggesting a possible link between EGFL7 expression and RR to
chemotherapy combined with bevacizumab.
The staining of EGFL7 resulted in varying degrees of unspecific
background staining. This may partly be due to the polyclonal
Figure 2. (A) Dark brown staining of endothelial-derived structures
along with a larger caldesmon-positive (red staining) blood vessel.
(B, C) Two examples of clusters of tumour cells with signs of
cytoplasmic EGFL7 expression and unspecific background staining
of the non-endothelial stromal compartment.
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nature of the antibody. The test of the antibody specificity
suggested a rather high specificity towards the EGFL7 protein in
that almost all staining was blocked. A lower than expected
frequency of neo-angiogenesis might also indicate that not all ECs
were visualised. This hypothesis was investigated in adjacent tissue
sections stained with CD34 in five cases with the visualisation of an
increased number of ECs compared with the anti-EGFL7 staining
(not shown). The shedding of the EGFL7 protein to the ECM to
support the sprouting angiogenetic process will lead to a non-EC-
specific expression at the tissue level, which may offer an additional
explanation as to the background staining. Furthermore, it is
possible that only high-EGFL7-expressing ECs were visualised,
and hence, anti-EGFL7 may identify blood vessels with a high
sprouting potential. EGFL7 expression was detected in cancer cells
too, as also reported by Wu et al (2009) in a study of patients with
hepatocellular carcinoma and by Li et al (2011) in a study on
squamous cell carcinoma. One explanation for these findings could
be the unspecific binding of the antibody. Other explanations could
be the autocrine stimulation of tumour cells by the ECs in the case
of hypoxia, in which the expression of EGFL7 is upregulated.
Table 2. Associations and correlations between the investigated parameters
Pri-miRNA-126 SNP genotype associations
Parameter N Genotypes
Median, 95% CI
Comparisons P-valuea
miRNA-126 15 AA: 2.53 (2.29–2.77) AA vs AG 0.051
58 AG: 2.20 (2.02–2.37) AA vs GG 0.180
46 GG: 2.30 (2.14–2.45) AG vs GG 0.392
EGFL7 tumour 22 AA: 0.62 (0.41–0.83) AA vs AG 0.276
71 AG: 0.51 (0.42–0.60) AA vs GG 0.634
68 GG: 0.58 (0.47–0.68) AG vs GG 0.380
EGFL7 invasive front 15 AA: 0.67 (0.44–0.91) AA vs AG 0.730
55 AG: 0.63 (0.50–0.76) AA vs GG 0.162
45 GG: 0.49 (0.37–0.61) AG vs GG 0.115
Correlations
Comparisons N Correlation coefficient (r) P-value
miRNA-126 vs EGFL7 tumour 118 0.09 0.348
miRNA-126 vs EGFL7 invasive front 116  0.10 0.281
EGFL7 tumour vs EGFL7 invasive front 119 0.47 o0.0001
Abbreviations: CI¼ confidence interval; EGFL7¼ epidermal growth factor-like domain 7; SNP¼ single-nucleotide polymorphism. N reflects the number of patient samples with complete data
for the individual analyses.
aP-values obtained by linear regression.
Table 3. Relations between the investigated parameters and response
rates
Response rates
Parameter
Response (N),
median
Non-response (N),
median P-value
Pri-miRNA-126
genotypes
(105) (117)
AA 12 15 —
AG 51 49 0.61a
GG 42 53 —
miRNA-126 (62) (64)
miRNA-126 2.32 2.29 0.65b
EGFL7 expression (84) (85)
Tumour 0.4 0.6 0.28b
EGFL7 expression (60) (62)
Invasive front 0.4 0.6 0.06b
Abbreviations: EGFL7¼ epidermal growth factor-like domain 7; miRNA-126¼microRNA-
126; Pri-miRNA-126¼primary microRNA-126.
aFischer’s exact test.
bWilcoxon rank sum test.
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Figure 3. Box plot illustrating the distribution of EGFL7 expression at
the invasive front according to response rates (n¼ 122, P¼ 0.06).
Boxes indicate the range from lower to upper quartile values, with the
line inside the box representing the median. The vertical lines mark
the highest and lowest value observed within a distance of 1.5 times the
inter-quartile range from the bottom and the top of the boxes,
respectively. Dots are outliers.
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Furthermore, a role of EGFL7 in Notch signalling seems possible
(Nichol and Stuhlmann, 2012), and the endocytosed complexes of
the EGFL7/Notch receptor may explain the detection of EGFL7 in
the cytoplasm of the CRC cells. Future studies will hopefully clarify
the optimal antibody and scoring technique for the interpretation
of EGFL7 expression.
The present results may point to a functional importance of the
pri-miRNA-126 SNP. Patients with the AA genotype demonstrated
a tendency towards a higher expression of mature miRNA-126 in
the tumours, although the difference was only marginally
significant. This is in accordance with the initial report by
Harnprasopwat et al (2010). As far as we know, the current pri-
miRNA-126 SNP has not been reported in patients with CRC
previously, but Yang et al (2011) presented a similar genotype
distribution in patients with breast cancer.
The miRNA-126 expression was not correlated with the EGFL7-
derived parameters, which is in accordance with previous findings
(Diaz et al, 2008). Post-transcriptional inhibition of the EGFL7
mRNA by miRNA-126 might be one explanation. Differences in
methodology and tumour heterogeneity may represent other
explanations. Furthermore, it is likely that miRNA-126 and EGFL7
transcriptions are regulated by different stimuli (Sun et al, 2010).
EGFL7 expression at the invasive front may be lower among the
responding patients, but this could not be concluded in the present
study. An inverse correlation between miRNA-126 and EGFL7
could be expected a priori. The miRNA-126 may target the EGFL7
mRNA. MicroRNA-126 is downregulated in malignant tissue,
whereas EGFL7 is upregulated in relation to carcinogenesis,
supporting the sprouting process of immature microvessels.
In contrast, miRNA-126 primarily governs the biological char-
acteristics of more mature blood vessels with higher vascular
integrity. We have previously demonstrated a relationship between
the high expression of miRNA-126 in the primary tumour and the
response to chemotherapy, and based on these findings, the present
relationship between EGFL7 and RR might not be surprising.
According to Delfortrie et al (2011), tumours with high EGFL7
expression are characterised by impaired blood vessel integrity,
representing an obstacle to the delivery of chemotherapy to the
tumour cells caused by a diminished pressure gradient, which is in
accordance with the present results. The possible relationship
between EGFL7 expression and RR was only seen regarding EGFL7
expression at the invasive front. This area characterises the growth
potential of the tumour, and it might also be exposed to a higher
degree to chemotherapy on account of higher interstitial pressure
in the central parts of the tumour.
The lack of correlation between miRNA-126 expression and RR
in the present study might be explained by differences in the
methodology and the treatment. The miRNA-126 expression was
estimated using the ISH supplied by an image-guided quantifica-
tion in the first study (Hansen et al, 2012) and RT-qPCR in the
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Figure 4. Progression-free survival curves according to (A) pri-miRNA-126 SNP genotypes (green¼GG, red¼AG, blue¼AA); (B) miRNA-126
expression levels (red¼ above median, blue¼below median); (C) EGFL7 expression in the tumour (red¼ above median, blue¼below
median); (D) EGFL7 expression at the invasive tumour front (red¼ above median, blue¼below median). N reflects the number of patients
randomised to maintenance treatment (patients with progressive disease were excluded per protocol) and thus differs from the base-line numbers
presented in Table 1.
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present study. Furthermore, the two treatment regimens differ
at one, perhaps very crucial, point, namely the addition of
anti-VEGF-A. It is likely that this addition may alter the predictive
value of an angiogenic marker such as miRNA-126. We observed
no difference in the relative miRNA-126 expression between
responders and non-responders (2.32 vs 2.29). However,
a subgroup analysis demonstrated a lower miRNA-126 expression
in patients with PD (1.91), although the statistical power of this
analysis was low (only nine patients).
The present findings on the prognostic value of miRNA-126
in patients with mCRC validate the previous results
(Hansen et al, 2012). An independent prognostic value
favouring patients with higher levels of miRNA-126 in their
primary tumour was documented. The prognostic value of
different miRNAs, including miRNA-126, was analysed by
Dı´az et al (2008) in a cohort of 110 patients with stage I through
IV colon cancer. Only 48 patients were at stage III or IV, and no
prognostic value of miRNA-126 was reported. This divergence,
compared with our results, may be explained by the rather
heterogeneous cohort of patients in the Dı´az study and the
rather limited number of patients with stage IV disease.
MicroRNA-126 may act as an inhibitor of the nesting
process of metastatic cells and may thereby inhibit the growth
potential of the metastatic disease (Tavazoie et al, 2008;
Png et al, 2011).
Why was the EGFL7 expression, with a possible relationship
to RR, not related to PFS? There seems to be a rather good
correlation between the two effect parameters, RR and PFS, in
first-line therapy, when the same treatment is given non-stop
until progression (Louvet et al, 2001). This was, however, not the
case in the present study. First of all, patient selection was
performed by randomisation, excluding patients with PD and
rendering the patient cohorts on induction treatment and
maintenance treatment non-identical. Second, the treatment
differs in that no chemotherapy is given during the maintenance
period, and third, randomisation was performed between two
different maintenance treatments. Hence, a correlation between
RR and PFS cannot be taken for granted in this situation.
One could speculate that high levels of EGFL7 would be related
to a high degree of neo-angiogenesis and a high sprouting
potential of immature and leaky blood vessels, representing an
obstacle to the delivery of chemotherapy to the malignant cells
under the induction treatment. These biological characteristics
might be of less importance during the chemotherapy-free
maintenance period, when treatment alone with anti-VEGF-A
(±anti-EGFR) might actually be of benefit to the high-EGFL7-
expressing tumours.
Although statistically significant results are presented, they do
not immediately justify individualised treatment decisions; how-
ever, they add to the increasing clinical knowledge about anti-
angiogenetics. The results might be of particular importance to
future treatment strategies, including both anti-VEGF-A and anti-
EGFL7 treatment of mCRC.
In conclusion, this study provides clinical data indicating a
relationship between miRNA-126 and the clinical outcome
of mCRC patients treated with chemotherapy combined
with anti-VEGF-A, whereas the impact of EGFL7 is more
speculative.
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Table 4. Cox regression analysis (n¼ 89 in the multiple analysis)
Simple analysis Multiple analysis
HR 95% CI P-value HR 95% CI P-value
Gender
Female 1 — — — — —
Male 0.94 0.65–1.35 0.735 — — —
Age
oMean 1 — — — — —
4Mean 1.04 0.72–1.48 0.850 — — —
Resection
No 1 — — — — —
Yes 0.88 0.61–1.28 0.513 — — —
Localisation
Colon 1 — — — — —
Rectum 0.94 0.64–1.39 0.773 — — —
Adjuvant chemotherapy
No 1 — — 1 — —
Yes 1.54 0.98–2.41 0.059 1.47 0.81–2.68 0.205
Metastatic sites
1 1 — — — — —
X2 1.22 0.87–1.73 0.252 — — —
Performance status
0 1 — — 1 — —
1–2 1.85 1.25–2.74 0.002 1.57 0.88–2.81 0.124
Pri-miRNA-126 SNP
AAþAG 1 — — — — —
GG 0.81 0.51–1.29 0.374 — — —
miRNA-126
oMedian 1 1
4Median 0.52 0.33–0.82 0.005 0.49 0.29–0.84 0.009
EGFL7 tumour
oMedian 1 — — — — —
4Median 0.81 0.55–1.21 0.303 — — —
EGFL7 invasive front
oMedian 1 — — — — —
4Median 0.85 0.54–1.35 0.490 — — —
Abbreviations: CI¼ confidence interval; EGFL7¼epidermal growth factor-like domain 7;
HR¼hazard ratio; SNP¼ single-nucleotide polymorphism. N¼ 89 refers to the number of
patients with complete data to be included in the multiple analysis.
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